A Phase 3 interventional study of TARA-002 and Investigator's Choice of Intravesical Chemotherapy in Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma and Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, sponsored by Protara Therapeutics. Recruiting at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Protara Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older.
The main questions it aims to answer are:
Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's planned enrollment of 284 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Protara Therapeutics is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For more information on eligibility criteria, please contact the Sponsor.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TARA-002
Drug: Investigator's Choice of Intravesical Chemotherapy
Drug pages: Picibanil · Lyophilized Inactivated Group A Streptococcus TARA-002
Participants will receive 6 weekly instillations of TARA-002. Participants confirmed to have a CR at Week 12 will enter the maintenance treatment period and will receive 3 additional weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. Participants who are eligible for reinduction at Week 12 will receive 6 additional weekly instillations of TARA-002. Participants who undergo reinduction and are confirmed to have a CR at Week 24 will enter the maintenance regimen treatment period and will receive 3 weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25.
Participants will receive 6 weekly instillations of Investigator's choice of intravesical chemotherapy. Participants confirmed to have a CR at Week 12 will enter the maintenance regimen treatment period and will receive one intravesical instillation of Investigator's choice of intravesical chemotherapy every 1 month up to Month 25.
Incidence of high-grade complete response
Incidence of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable)
Time frame: Month 6
Duration of high-grade complete response
Duration of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Treatment emergent adverse events
Incidence and severity of treatment emergent adverse events (TEAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Treatment emergent serious adverse events
Incidence and severity of treatment emergent serious adverse events (TESAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
High-grade complete response rate
High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable)
Time frame: At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60
High-grade complete response rate (CIS only)
High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) in sub-group of participants with CIS only
Time frame: Month 6
Event-free survival
Event-free survival (EFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Recurrence-free survival
Recurrence-free survival (RFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Progression-free survival
Progression-free survival (PFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Disease-specific progression-free survival
Disease-specific progression-free survival (DSPFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up ro Month 60
Overall survival
Overall survival (OS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Disease-specific survival
Disease-specific survival (DSS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Time to cystectomy
Time to cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Time to recurrence delayed cystectomy
Time to recurrence delayed cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Time to progression
Time to progression of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Time to disease worsening
Time to disease worsening of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy
Time frame: Up to Month 60
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Apr 2028, 23 months after the start.
Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's planned 23 months is below that.
Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Picibanil · Lyophilized Inactivated Group A Streptococcus TARA-002
Protara Therapeutics